1. Home
  2. SATL vs ANAB Comparison

SATL vs ANAB Comparison

Compare SATL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$7.12

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$50.37

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SATL
ANAB
Founded
2010
2005
Country
United States
United States
Employees
154
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SATL
ANAB
Price
$7.12
$50.37
Analyst Decision
Strong Buy
Buy
Analyst Count
3
12
Target Price
$5.50
$71.67
AVG Volume (30 Days)
9.3M
542.3K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
N/A
$234,603,000.00
Revenue This Year
$88.89
N/A
Revenue Next Year
$56.98
$52.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.01
52 Week Low
$1.26
$17.11
52 Week High
$12.00
$73.30

Technical Indicators

Market Signals
Indicator
SATL
ANAB
Relative Strength Index (RSI) 39.71 31.21
Support Level $6.13 $43.75
Resistance Level $8.18 $51.67
Average True Range (ATR) 0.93 2.68
MACD -0.39 -0.99
Stochastic Oscillator 0.68 5.47

Price Performance

Historical Comparison
SATL
ANAB

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: